Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Development of N-(4-(1H-Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability

  • Michela Puxeddu
  • , Lele Ling
  • , Silvia Ripa
  • , Michele D'Ambrosio
  • , Marianna Nalli
  • , Anastasia Parisi
  • , Pietro Sciò
  • , Antonio Coluccia
  • , Arianna Granese
  • , Martina Santelli
  • , Domiziana Masci
  • , Petra Cuřínová
  • , Chiara Naro
  • , Claudio Sette
  • , Arianna Pastore
  • , Mariano Stornaiuolo
  • , Chiara Bigogno
  • , Giulio Dondio
  • , Laura Di Magno
  • , Gianluca Canettieri*
  • Te Liu*, Romano Silvestri*, Giuseppe La Regina
*Autore corrispondente per questo lavoro
  • University of Rome La Sapienza
  • Shanghai Jiao Tong University
  • Sapienza University
  • University of Chemistry and Technology, Prague
  • University of Naples Federico II
  • Shanghai University of Traditional Chinese Medicine

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

The potential as a cancer therapeutic target of the recently reported hotspot binding region close to Lys508 of the beta-catenin armadillo repeat domain was not exhaustively explored. In order to get more insight, we synthesized novel N-(heterocyclylphenyl)benzenesulfonamides 6-28. The new compounds significantly inhibited Wnt-dependent transcription as well as SW480 and HCT116 cancer cell proliferation. Compound 25 showed binding mode consistent with this hotspot binding region. Compound 25 inhibited the growth of SW480 and HCT116 cancer cells with IC50's of 2 and 0.12 mu M, respectively, and was superior to the reference compounds 5 and 5-FU. 25 inhibited the growth of HCT-116 xenografted in BALB/Cnu/nu mice, reduced the expression of the proliferation marker Ki67, and significantly affected the expression of cancer-related genes. After incubation with human and mouse liver microsomes, 25 showed a higher metabolic stability than 5. Compound 25 aims to be a promising lead for the development of colorectal cancer anticancer therapies.
Lingua originaleInglese
pagine (da-a)20298-20314
Numero di pagine17
RivistaJournal of Medicinal Chemistry
Numero di pubblicazionen/a
DOI
Stato di pubblicazionePubblicato - 2024

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

  1. SDG 3 - Salute e benessere
    SDG 3 Salute e benessere

All Science Journal Classification (ASJC) codes

  • Medicina Molecolare
  • Nuovi Farmaci

Keywords

  • inglese

Fingerprint

Entra nei temi di ricerca di 'Development of N-(4-(1H-Imidazol-1-yl)phenyl)-4-chlorobenzenesulfonamide, a Novel Potent Inhibitor of β-Catenin with Enhanced Antitumor Activity and Metabolic Stability'. Insieme formano una fingerprint unica.

Cita questo